Biofrontera (BFRI) news
Recent news
BioFrontera - To launch SBCC indication late Q4 2026 through Q1 2027
BioFrontera Inc. (BFRI) has outlined a regulatory timeline for the approval of its product Ameluz for the treatment of superficial basal cell carcinoma (sBCC). The U.S. Food and Drug Administration (FDA) has set PDUFA date of September 28 , 2026, for the review of the sBCC indication filing. Based…
AInvest Wire · Sep 14, 2026Biofrontera Q2 EPS USD -0.05
Biofrontera Inc. (BFRI) reported its Q2 2026 earnings on August 7, 2026, with an earnings per share (EPS) of -$0.05, surpassing the estimated EPS by 50%. The company’s revenue for the quarter is expected to reach $9.50 million, in line with analyst projections . This represents a slight decline…
AInvest Wire · Aug 13, 2026Biofrontera Q2 adjusted EBITDA USD -200 thousand
Biofrontera Inc. reported an adjusted EBITDA loss of $200,000 for the second quarter of 2026, according to its financial disclosures. This represents a significant shift from the positive adjusted EBITDA of $4.9 million in the fourth quarter of 2025, highlighting fluctuating financial performance .…
AInvest Wire · Aug 13, 2026Biofrontera Q2 revenue USD 12 million
Biofrontera Inc. (BFRI) reported second-quarter revenue of USD 12 million for the period ending June 30, 2025. The company provided the earnings update during its Q2 2025 earnings call, offering insights into its financial performance and operational progress. While specific details on…
AInvest Wire · Aug 13, 2026Biofrontera Inc. Announces Preliminary Q3 Revenues Of ~$8.7M-$9M Vs $7.03M Est.; Affirms Guidance For Full-Year Revenue Growth Of At Least 25% Over 2022
AInvest Wire · Oct 4, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.